

July 4, 2018  
 Symbio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director,  
 President and Chief Executive Officer

**Notice of the Large Volume Exercise of the 45<sup>th</sup> Stock Acquisition Rights (with Exercise Price Revision Clauses)  
 Issued by way of Third Party Allotment**

TOKYO, Japan, July 4, 2018—Symbio Pharmaceuticals Limited announces the large volume exercise of the 45<sup>th</sup> stock acquisition rights, allotted to EVO FUND based on the board resolution announced on April 9, 2018, during the period from July 2, 2018 to July 4, 2018, as below.

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 45 <sup>th</sup> Stock Acquisition Rights
(2)	Number of issued shares from the beginning of the month	2,000,000 shares
(3)	Number of stock acquisition rights being exercised from the beginning of the month and the ratio to the entire issue	2,000,000 units (Ratio to the total number of stock acquisition rights issued 20,000,000 units : 10.00%)
(4)	Number of unexercised stock acquisition rights at the end of previous month	15,500,000 units
(5)	Number of remaining unexercised stock acquisition rights as of today	13,500,000 units

6. Exercise status from the beginning of the month

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
July 2 (Mon.)	—	—	141	—
July 3 (Tue.)	—	—	141	—
July 4 (Wed.)	2,000,000	—	136	2,000,000

※Number of issued shares at the end of the previous month : 62,353,224 shares [of which 75 shares are treasury shares]

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45<sup>th</sup> through 47<sup>th</sup> Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.